Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW/CF) stimulates cell proliferation in HUVEC human umbilical vein endothelial cells. The ED50 is 2‑8 ng/mL.
1 μg/lane of Recombinant Human TWEAK/TNFSF12 was resolved withSDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 19 kDa.
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.
Applications/Dilutions
Dilutions
Bioactivity
Theoretical MW
18.3 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Publications
Read Publications using 1090-TW/CF in the following applications:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS.
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human TWEAK/TNFSF12 Protein, CF
APO3 ligand
APO3LMGC20669
DR3LGTWEAKAPO3/DR3 ligand
MGC129581
TNF-related weak inducer of apoptosis
TNFSF12
tumor necrosis factor (ligand) superfamily, member 12
tumor necrosis factor ligand superfamily member 12
TWEAK
Background
TWEAK is a type II transmembrane protein belonging to the TNF superfamily (1). It contains a short cytoplasmic domain (aa 1‑18), the transmembrane domain (aa 19-42) and an extracellular domain (aa 43-249). The extracellular domains of human and murine TWEAK share 89% aa sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecules by proteolytic cleavage after Arg 93 suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells. At least two receptors that bind TWEAK have been identified (2-4). Death Receptor 3 (DR3), also known as TNFRSF12, Apo-3, LARD, WSL-1 or TRAMP, is a TNF receptor superfamily member that is expressed predominantly in tissues with high lymphocyte content (2). It has been suggested that induction of cell death by TWEAK-DR3 interaction involves the activation of NF-kappa B. In cells that lack DR3, alternate pathways of TWEAK-induced cell death mediated by receptors distinct from DR3 have been suggested (5, 6). TWEAK receptor (TWEAKR, alternatively known as FN14), is a novel TNF receptor superfamily member that also binds TWEAK (3, 4). It is a mitogen-inducible gene that is expressed in fibroblasts, hepetocellular carcinomas and endothelial cells. TWEAK-TWEAKR interaction has been shown to play a role in endothelial cell growth and migration. This effect of TWEAK is not mediated by an up-regulation of VEGF (7).
Chicheportiche, Y. et al. (1997) J. Biol Chem. 272:32401.
Marsters, S. et al. (1998) Current Biol. 8:525.
Wiley, S. R. et al. (2001) Immunity, 15:837.
Feng, S.-L.Y. et al. (2000) Am J. Path. 156:1253.
Nakayama, M. et al. (2002) J. Immunol. 168:734.
Schneider, P. et al. (1999) Eur. J. Immunol., 29:1785.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our Recombinant Human TWEAK/TNFSF12 Protein, CF and receive a gift card or discount.